- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03232086
Responses to Exposure to Low Levels of Concentrated Ambient Particles in Healthy Young Adults (RECAP)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Air pollution is associated with several adverse health outcomes. Specifically, ambient fine particulate matter ≤2.5 μg/m3 (PM2.5) is associated with increased mortality and increased risk for respiratory and cardiovascular disease It has been estimated that worldwide over 3.2 million premature deaths and over 74 million years of healthy life lost were attributable to ambient particulate matter pollution, making it one of the top global health risk factors . Further, an estimated 22% of disability-adjusted life-years for heart disease are attributable to ambient particulate matter pollution. Similarly, it is estimated that air pollution exposure contributed to about 6% (3.7 million) of all deaths in 2012, with 40% of those coming from coronary artery disease (CAD). More than 100 time-series and case-crossover analyses have demonstrated associations of short term PM2.5 exposure with myocardial infarctions (MIs); aggravated asthma and increased risk for hospitalizations and mortality. These studies suggest that the acute health effects of air pollution particularly affect infants and children, older adults, and those with underlying disease, such as diabetes and cardiovascular disease (Pope, 2014). In healthy and younger individuals (<65 year old) these same studies observe associations between air pollution and subclinical biomarkers of inflammation, coagulation and oxidative stress but not for any clinical outcomes. This has led the American Heart Association to state that" Despite theoretical statistical risks ascribed to all individuals, this elevated risk from exposure is not equally distributed within a population. At present-day levels, PM2.5 likely poses an acute threat principally to susceptible people, even if seemingly healthy, such as the elderly and those with (unrecognized) existing coronary artery or structural heart disease."
Controlled human exposure studies are a critical component of the health risk assessment for ozone because of their ability to establish exposure-response relationships at low doses and have therefore weighed heavily in deliberations when the U.S. EPA has considered the National Ambient Air Quality Standard (NAAQS). In contrast, for PM2.5, controlled exposure studies have been used primarily to demonstrate biological plausibility. that is the potential for particulate matter to exert extra-pulmonary effects. These studies have shown that healthy volunteers primarily exhibit mild pulmonary inflammation, decreases in heart rate variability and changes in blood factors associated with blood coagulation following exposure to concentrated air particles (CAPs), most show no change in lung function and none result in cardiac arrhythmia. Nearly all these studies have been conducted at realistic but high levels of PM2.5 (typically above 100 µg/m3). Currently the EPA 24-hour fine particle standard is 35µg/m3, a value based predominantly on epidemiologic studies. While epidemiologic studies suggest that similar effects can occur at lower levels, it is difficult for these association studies to conclusively demonstrate because of the problems in disassociating the effects of PM2.5 from other pollutants and confounders. Only a controlled human exposure study can determine directly whether PM2.5 can alter cardiovascular endpoints at lower concentrations. Four hours represents a typical exposure duration to particulate matter during the course of the day.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- U.S. EPA Human Studies Facility
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Healthy individuals ages 18-35 years of age
- Physical conditioning allowing intermittent, moderate exercise for four hours. Ability to complete the exposure exercise regimen without reaching 80% of predicted maximal heart rate. Predicted maximal heart rate will be calculated using the equation (described by Tanaka et al.: [2001] J. Am. Coll. Cardiol.): [208bpm-((0.7) x (age in years))]
- Normal baseline 12-lead EKG .
Normal lung function
- Forced vital capacity (FVC) ≥ 80% of that predicted for gender, ethnicity, age and height (according to NHANESIII guidelines).
- Forced expiratory volume in one second (FEV1) ≥ 80%of that predicted for gender,ethnicity, age and height
- FEV1) /FVC ratio≥ 80% of predicted values.
- Oxygen saturation ≥ 96% on room air.
Exclusion Criteria:
- Individuals with a history of acute or chronic cardiovascular disease, chronic respiratory disease, diabetes, rheumatologic diseases, or immunodeficiency state.
- Individuals with a CVD risk score greater than 10% using the ACC/AHA ASCVD risk calculator.
- Individuals with clinically diagnosed asthma.
- Individuals who are allergic to chemical vapors or gases.
- Females who are pregnant, attempting to become pregnant, or breastfeeding.
- Individuals that are unable or unwilling to stop for at least two weeks prior to the study taking medications, vitamins or supplements that the investigators believe may impact the results of the study. Those not specifically mentioned here may be reviewed by the investigators prior to an individual's inclusion in the study.
- Individuals who smoke/vape more than 2 times per month and have smoked/vaped within 4 weeks prior to all study visits.
- Individuals living with a smoker who smokes inside the house.
- Individuals with a body mass index (BMI) >35 or <18. Body mass index is calculated by dividing the weight in kilograms by the square of the height in meters.
- Individuals with occupational exposures to high levels of vapors, dust, gases, or fumes on an on-going basis.
- Individuals with uncontrolled hypertension (≥150 systolic or ≥90 diastolic).
- Individuals that do not understand or speak English.
- Individuals that are unable to perform the exercise required for the study.
- Individuals that are taking beta blocker medications.
- Individuals with a history of skin allergies to adhesives used in securing EKG electrodes.
- Individuals with unspecified diseases, conditions, or medications that might influence the responses to the exposures, as judged by the medical staff.
- Individuals that are unwilling or unable to stop taking over-the-counter pain medications such as aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), or other non-steroidal anti-inflammatory ("NSAID") medications for 48 hours prior to the exposures and post-exposure visits.
- Individuals that are taking systemic steroids or beta-blocker medications.
- Individuals with a hemoglobin A1c (HbA1c) level > 6.4%.
Temporary Exclusion Criteria:
- Individuals suffering from acute respiratory illness within four weeks prior to any of the study exposure series.
- Individuals that have been exposed to smoke and fumes within 24 hours of any study visit.
- Individuals that have engaged in strenuous exercise within 24 hours of any study visit.
- Individuals that have been exposed to ozone-based home air purifiers within 24 hours of any study visit.
- Individuals unable to avoid drinking alcohol for 24 hours prior to all study visits.
- Individual unable to avoid caffeine for 12 hours prior to all study visits and during each study visit.
- Individuals that have been exposed to unvented household combustion sources (gas stoves, lit fireplaces, oil/kerosene heaters) within 48 hours of any study visit.
- Individuals that have been exposed to or have consumed any agent or have undertaken any activity within 24 hours of any study visit that the investigators believe may compromise the results of the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador falso: Aire limpio
La exposición al aire limpio se llevará a cabo en una cámara de exposición en el Centro de Estudios Humanos de la EPA en el campus de la UNC.
|
Each subject will be exposed to clean air for 4 hours.
Subjects will exercise on a bike or treadmill.
Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
|
Comparador activo: Concentrated PM2.5
Exposure to PM2.5 will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
|
Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours.
Subjects will exercise on a bike or treadmill.
Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Changes in heart rate variability
Periodo de tiempo: Pre exposure to 24hours post exposure
|
10 minute electrocardiogram recording (measured by Holter ECG) in which the
|
Pre exposure to 24hours post exposure
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Volumen espirado forzado en el primer segundo (FEV1)
Periodo de tiempo: Pre exposición a 24 horas después de la exposición
|
El volumen espirado forzado en el primer segundo (FEV1) se determina mediante una espirometría realizada en un espirómetro de sello seco conectado a una computadora.
|
Pre exposición a 24 horas después de la exposición
|
Capacidad vital forzada
Periodo de tiempo: Pre exposición a 24 horas después de la exposición
|
La capacidad vital forzada (FVC) se determina mediante una espirometría realizada en un espirómetro de sello seco conectado a una computadora.
|
Pre exposición a 24 horas después de la exposición
|
Index of inflammatory markers
Periodo de tiempo: Pre exposure to 24hours post exposure
|
Index of inflammatory markers is the mean % changes in a basket of factors related to systemic inflammation (IL-6, IL-8, TNF-a, IL-b, CRP) in the blood following exposure to PM2.5 vs. clean air.
|
Pre exposure to 24hours post exposure
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- 16-1548
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Exposición a la contaminación
-
University of California, San FranciscoTerminadoAdicción a la comida | Cómo se relacionó el tono opioide con el autoinforme | Drive to Eat usando una medida de adicción a la comida
Ensayos clínicos sobre Clean Air
-
National Institutes of Health Clinical Center (CC)ReclutamientoTerapia de dietaEstados Unidos
-
Megadyne Medical Products Inc.DesconocidoAbdominoplastia | Reducción mamaria bilateral | Levantamiento de senos bilateral | Braquioplastia Bilateral | Lifting Lateral Bilateral de Muslos y GlúteosEstados Unidos
-
Massachusetts General HospitalTerminadoAsfixia Perinatal | Asfixia neonatal | Asfixia de nacimiento
-
Johns Hopkins UniversityRetirado
-
CIBA VISIONTerminadoPresbicia | Astigmatismo | Miopía
-
air up GmbHCitruslabsReclutamiento
-
ResMedTerminadoRespiración trastornada del sueñoEstados Unidos
-
Chang Gung Memorial HospitalReclutamiento
-
ResMedTerminadoApnea del Sueño ObstructivaEstados Unidos